however there were differences in the biomarkers that look hopeful. The dosing regimen in phase 3 is greater so only time will tell us if that translates to clinical effects but I think one could be cautiously optimistic
The reason they upped the dosing regimen in Phase 3 was to attempt to boost the signal seen in Phase 2. If there had been no signal, Phase 3 would not have been undertaken.